8-K Announcements
6Material company update
Mar 24, 2026·SEC
Material company update
Jan 22, 2026·SEC
Material company update
Jan 20, 2026·SEC
BioAge Labs, Inc.(BIOA)Earnings, Financials & Key Ratios
BIOA•NASDAQ
$18.46
$664M mkt cap·Price updated May 6, 2026
AboutBioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.Show more
- Revenue$9M
- EBITDA-$93M-18.6%
- Net Income-$81M-13.4%
- EPS (Diluted)-2.24+66.2%
- Gross Margin100%
- EBITDA Margin-1029.09%
- Operating Margin-1031.46%
- Net Margin-896.11%
- ROE-27.09%+71.5%
- ROIC-210.21%
- Debt/Equity0.02-24.1%
- Interest Coverage-133.11-358.4%
BIOA Key Insights
BioAge Labs, Inc. (BIOA) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Momentum leader: RS Rating 93 (top 7%)
✗Weaknesses
- ✗Negative free cash flow
- ✗Shares diluted 100.0% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
BIOA Price & Volume
BioAge Labs, Inc. (BIOA) stock price & volume — 10-year historical chart
Loading chart...
BIOA Growth Metrics
BioAge Labs, Inc. (BIOA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-13.35%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM81.65%
Return on Capital
10 Years-86.74%
5 Years-86.74%
3 Years-41.55%
Last Year-30.66%
BIOA Recent Earnings
BioAge Labs, Inc. (BIOA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (50%)●Beat Revenue 4/12 qtrs (100%)
Q2 2026Latest
Mar 24, 2026EPS
$0.72
Est $0.83
+13.3%
Revenue
$3M
Est $1M
+119.9%
Q4 2025
Nov 6, 2025EPS
$0.56
Est $0.67
+16.4%
Revenue
$2M
Est $1M
+80.2%
Q3 2025
Aug 6, 2025EPS
$0.60
Est $0.56
-7.1%
Revenue
$2M
Est $870,000
+177.2%
Q2 2025
May 6, 2025EPS
$0.36
Est $0.52
+30.8%
Revenue
$1M
Est $580,000
+150.2%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 24, 2026 | $0.72vs $0.83+13.3% | $3Mvs $1M+119.9% |
| Q4 2025 | Nov 6, 2025 | $0.56vs $0.67+16.4% | $2Mvs $1M+80.2% |
| Q3 2025 | Aug 6, 2025 | $0.60vs $0.56-7.1% | $2Mvs $870,000+177.2% |
| Q2 2025 | May 6, 2025 | $0.36vs $0.52+30.8% | $1Mvs $580,000+150.2% |
Based on last 12 quarters of dataView full earnings history →
BIOA Peer Comparison
BioAge Labs, Inc. (BIOA) competitors in Metabolic and Obesity Therapies — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 KYMR | 7.04B | 86.26 | -23.38 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RVMD | 32.12B | 151.07 | -25.39 | -83.22% | 0.10 | |||
 LNTH | 5.61B | 86.15 | 25.26 | 0.5% | 15.15% | 20.58% | 0.00 | |
 RYTM | 6.6B | 96.61 | -31.06 | 45.83% | -93.84% | -204.35% | 1.77 | |
 VNDA | 439.76M | 7.44 | -1.99 | 8.72% | -102.02% | -49.24% | 0.04 | |
 NUVL | 6.92B | 104.26 | -26.53 | -45.12% | ||||
 IMVT | 5.83B | 28.67 | -10.50 | -47.07% | 0.00 | |||
 ARDX | 1.74B | 7.10 | -27.31 | 22.09% | -13.58% | -38.11% | 1.27 |
Compare BIOA vs Peers
BioAge Labs, Inc. (BIOA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BIOA Income Statement
BioAge Labs, Inc. (BIOA) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 8.99M |
| Revenue Growth % | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 213K |
| COGS % of Revenue | - | - | - | 2.37% |
| Gross Profit | 0▲ 0% | 0▲ 0% | 0▲ 0% | 8.99M▲ 0% |
| Gross Margin % | - | - | - | 100% |
| Gross Profit Growth % | - | - | - | - |
| Operating Expenses | 39.97M | 48.4M | 78.19M | 101.78M |
| OpEx % of Revenue | - | - | - | 1131.46% |
| Selling, General & Admin | 9.45M | 14.51M | 19.16M | 27.81M |
| SG&A % of Revenue | - | - | - | 309.16% |
| Research & Development | 30.52M | 33.89M | 59.04M | 73.97M |
| R&D % of Revenue | - | - | - | 822.3% |
| Other Operating Expenses | 0 | 0 | 0 | 0 |
| Operating Income | -39.97M▲ 0% | -48.4M▼ 21.1% | -78.19M▼ 61.6% | -92.78M▼ 18.7% |
| Operating Margin % | - | - | - | -1031.46% |
| Operating Income Growth % | - | -21.09% | -61.56% | -18.65% |
| EBITDA | -39.84M | -48.24M | -78.03M | -92.57M |
| EBITDA Margin % | - | - | - | -1029.09% |
| EBITDA Growth % | - | -21.08% | -61.75% | -18.63% |
| D&A (Non-Cash Add-back) | 129K | 162K | 167K | 213K |
| EBIT | -39.48M | -56.06M | -68.74M | -92.78M |
| Net Interest Income | 224K | -5.36M | 7.26M | 12.39M |
| Interest Income | 465K | 2.43M | 9.63M | 13.09M |
| Interest Expense | 241K | 7.79M | 2.37M | 697K |
| Other Income/Expense | 247K | -15.45M | 7.08M | 12.18M |
| Pretax Income | -39.72M▲ 0% | -63.85M▼ 60.8% | -71.11M▼ 11.4% | -80.61M▼ 13.4% |
| Pretax Margin % | - | - | - | -896.11% |
| Income Tax | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% |
| Net Income | -39.72M▲ 0% | -63.85M▼ 60.8% | -71.11M▼ 11.4% | -80.61M▼ 13.4% |
| Net Margin % | - | - | - | -896.11% |
| Net Income Growth % | - | -60.75% | -11.36% | -13.35% |
| Net Income (Continuing) | -39.72M | -63.85M | -71.11M | -80.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.32▲ 0% | -8.55▼ 60.7% | -6.63▲ 22.5% | -2.24▲ 66.2% |
| EPS Growth % | - | -60.71% | 22.46% | 66.21% |
| EPS (Basic) | -5.32 | -8.55 | -6.63 | -2.24 |
| Diluted Shares Outstanding | 7.46M | 7.47M | 10.73M | 35.93M |
| Basic Shares Outstanding | 7.46M | 7.47M | 10.73M | 35.93M |
| Dividend Payout Ratio | - | - | - | - |
BIOA Balance Sheet
BioAge Labs, Inc. (BIOA) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Total Current Assets | 28.03M | 25.31M | 357.1M | 286.79M |
| Cash & Short-Term Investments | 27.64M | 21.64M | 354.35M | 281.1M |
| Cash Only | 27.64M | 21.64M | 354.35M | 188.89M |
| Short-Term Investments | 0 | 0 | 0 | 92.21M |
| Accounts Receivable | 0 | 0 | 0 | 769K |
| Days Sales Outstanding | - | - | - | 31.2 |
| Inventory | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - |
| Other Current Assets | 386K | 3.66M | 2.75M | 4.93M |
| Total Non-Current Assets | 399K | 618K | 1.13M | 8.1M |
| Property, Plant & Equipment | 374K | 518K | 791K | 3.75M |
| Fixed Asset Turnover | - | - | - | 2.40x |
| Goodwill | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 100K | 100K | 100K |
| Other Non-Current Assets | 25K | 0 | 240K | 4.25M |
| Total Assets | 28.43M▲ 0% | 25.92M▼ 8.8% | 358.23M▲ 1281.9% | 294.89M▼ 17.7% |
| Asset Turnover | - | - | - | 0.03x |
| Asset Growth % | - | -8.81% | 1281.86% | -17.68% |
| Total Current Liabilities | 5.86M | 58.17M | 27.77M | 20.14M |
| Accounts Payable | 2.26M | 1.87M | 2M | 2.67M |
| Days Payables Outstanding | - | - | - | 4.58K |
| Short-Term Debt | 167K | 44.86M | 6M | 3.23M |
| Deferred Revenue (Current) | 0 | 3.31M | 7.83M | 5.75M |
| Other Current Liabilities | 24K | 1.39M | 417K | 8.48M |
| Current Ratio | 4.78x | 0.44x | 12.86x | 14.24x |
| Quick Ratio | 4.78x | 0.44x | 12.86x | 14.24x |
| Cash Conversion Cycle | - | - | - | - |
| Total Non-Current Liabilities | 135.13M | 141.15M | 7.33M | 2.7M |
| Long-Term Debt | 2.25M | 8.2M | 2.5M | 2.33M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 132.88M | 132.95M | 156K | 370K |
| Total Liabilities | 140.99M | 199.32M | 35.11M | 22.84M |
| Total Debt | 2.47M | 53.25M | 8.7M | 5.56M |
| Net Debt | -25.18M | 31.61M | -345.64M | -183.33M |
| Debt / Equity | - | - | 0.03x | 0.02x |
| Debt / EBITDA | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - |
| Interest Coverage | -163.82x | -7.19x | -29.04x | -133.11x |
| Total Equity | -112.56M▲ 0% | -173.4M▼ 54.0% | 323.13M▲ 286.4% | 272.05M▼ 15.8% |
| Equity Growth % | - | -54.05% | 286.35% | -15.81% |
| Book Value per Share | -15.09 | -23.23 | 30.12 | 7.57 |
| Total Shareholders' Equity | -112.56M | -173.4M | 323.13M | 272.05M |
| Common Stock | 0 | 0 | 0 | 0 |
| Retained Earnings | -117.85M | -181.7M | -252.81M | -333.42M |
| Treasury Stock | 0 | 0 | 0 | 0 |
| Accumulated OCI | 167K | 164K | 245K | 278K |
| Minority Interest | 0 | 0 | 0 | 0 |
BIOA Cash Flow Statement
BioAge Labs, Inc. (BIOA) cash flow — operating, investing & free cash flow history
| Line item | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|
| Cash from Operations | -36.18M | -37.36M | -51.52M | -81.63M |
| Operating CF Margin % | - | - | - | -907.47% |
| Operating CF Growth % | - | -3.26% | -37.9% | -58.43% |
| Net Income | -39.72M | -63.85M | -71.11M | -80.61M |
| Depreciation & Amortization | 129K | 162K | 167K | 213K |
| Stock-Based Compensation | 2.54M | 3.02M | 6.98M | 11.69M |
| Deferred Taxes | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 77K | 16.6M | 1.26M | -1.1M |
| Working Capital Changes | 795K | 6.71M | 11.18M | -11.83M |
| Change in Receivables | 0 | 0 | 0 | -769K |
| Change in Inventory | 0 | 0 | 0 | 0 |
| Change in Payables | 994K | -393K | 6K | 788K |
| Cash from Investing | -103K | -266K | -366K | -95.22M |
| Capital Expenditures | -103K | -166K | -366K | -719K |
| CapEx % of Revenue | - | - | - | 7.99% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 |
| Cash from Financing | 2.5M | 34.94M | 381.2M | 11.47M |
| Debt Issued (Net) | 2.5M | 35M | -6M | -6M |
| Equity Issued (Net) | 0 | 0 | 391.62M | 17.47M |
| Dividends Paid | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | -1K | -59K | -4.42M | 0 |
| Net Change in Cash | -33.54M▲ 0% | -2.69M▲ 92.0% | 329.39M▲ 12358.7% | -165.46M▼ 150.2% |
| Free Cash Flow | -36.28M▲ 0% | -37.53M▼ 3.4% | -51.89M▼ 38.3% | -82.35M▼ 58.7% |
| FCF Margin % | - | - | - | -915.46% |
| FCF Growth % | - | -3.43% | -38.26% | -58.7% |
| FCF per Share | -4.86 | -5.03 | -4.84 | -2.29 |
| FCF Conversion (FCF/Net Income) | 0.91x | 0.59x | 0.72x | 1.01x |
| Interest Paid | 129K | 1.16M | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 |
BIOA Key Ratios
BioAge Labs, Inc. (BIOA) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -94.98% | -27.09% |
| Return on Invested Capital (ROIC) | - | - | - | -210.21% |
| Gross Margin | - | - | - | 100% |
| Net Margin | - | - | - | -896.11% |
| Debt / Equity | - | - | 0.03x | 0.02x |
| Interest Coverage | -163.82x | -7.19x | -29.04x | -133.11x |
| FCF Conversion | 0.91x | 0.59x | 0.72x | 1.01x |
BIOA SEC Filings & Documents
BioAge Labs, Inc. (BIOA) SEC filings — annual & quarterly reports (10-K, 10-Q)
BIOA Frequently Asked Questions
BioAge Labs, Inc. (BIOA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
BioAge Labs, Inc. (BIOA) reported $9.0M in revenue for fiscal year 2025.
BioAge Labs, Inc. (BIOA) grew revenue by 0.0% over the past year. Growth has been modest.
BioAge Labs, Inc. (BIOA) reported a net loss of $80.6M for fiscal year 2025.
Dividend & Returns
BioAge Labs, Inc. (BIOA) has a return on equity (ROE) of -27.1%. Negative ROE indicates the company is unprofitable.
BioAge Labs, Inc. (BIOA) had negative free cash flow of $82.3M in fiscal year 2025, likely due to heavy capital investments.
Explore More BIOA
BioAge Labs, Inc. (BIOA) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates